Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607349 | 0.91 | CA12 (0.44) | MIFHSD17B3ABCG2CA12CA1 | |
| SCHEMBL5607413 | 0.87 | MIF (0.49) | MIFHSD17B3CA12CA1CA2 | |
| SCHEMBL6062333 | 0.85 | MIF (0.48) | MIFHSD17B3ABCG2CA12CA1 | |
| SCHEMBL5607546 | 0.85 | ESR1 (0.51) | MIFHSD17B3ABCG2CA12CA1 | |
| SCHEMBL10924807 | 0.84 | MIF (0.49) | MIFHSD17B3ABCG2ALOX5KDM4E | |
| SCHEMBL5607567 | 0.84 | MIF (0.47) | MIFHSD17B3ABCG2CA12CA1 | |
| SCHEMBL5606981 | 0.84 | ESR1 (0.47) | MIFABCG2CA12CA1CA2 | |
| SCHEMBL29741641 | 0.83 | ALOX5 (0.52) | MIFHSD17B3ALOX5KDM4EALDH1A1 | |
| SCHEMBL5607169 | 0.83 | ALOX5 (0.52) | MIFHSD17B3ALOX5KDM4EALDH1A1 | |
| SCHEMBL2187658 | 0.82 | LMNA (0.55) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1687250-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | Takasago International Corporation (JP) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051882-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | ALDH1A2, ALDH1A3, GRHPR | MIF 2713/4885HSD17B3 287/4885ABCG2 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.